Cite
MLA Citation
Gautam Borthakur et al.. “BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study.” Cancer, vol. 127, no. 8, 2021, pp. 1246–1259. http://access.bl.uk/ark:/81055/vdc_100127487084.0x00003c